Simris Group deepened its focus on biopharma and ADC payloads in 2024, but continued to post losses and faces significant liquidity risks, requiring new capital to sustain operations through 2025. Auditors highlight material uncertainty about going concern.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.